摘要：近日，通用電氣公司宣佈將以214億美元的價格將其生物製藥業務出售給丹納赫，週一GE股價大漲11%。這是GE新任首席執行長拉里·庫珀( Larry Culp )領導下的首次重大資產出售。
Shares of General Electric Co surged 11 percent on Monday after the U.S. industrial conglomerate said it would sell its biopharma business to Danaher Corp for $21。4 billion, its first major asset sale under new Chief Executive Officer Larry Culp.
通用電氣公司股價週一大漲11%，此前這家美國工業集團表示，將以214億美元的價格將其生物製藥業務出售給丹納赫公司，這是該公司新任首席執行長拉里·庫珀( Larry Culp )領導下的首次重大資產出售。
The deal will provide GE with a much needed cash infusion as the maker of power plants and aircraft engines struggles to pay off billions of dollars of debt and insurance liabilities.
該交易將為通用電氣提供急需的現金注入，因為這家發電廠和飛機引擎製造商正努力償還數十億美元的債務和保險債務。
GE, once a symbol of American business power and management prowess, has struggled with crisis-era losses linked to its finance arm, forcing it to divest its non-core businesses and rebuild its industrial business.
通用電氣曾是美國商業實力和管理能力的象徵，但該公司一直在努力應對與其金融部門相關的危機時代虧損，迫使其剝離非核心業務，重建工業業務。
Culp said the sale to Danaher, where he was chief executive for more than a decade until 2014, was a pivotal milestone in efforts to turn around the 126-year old conglomerate.
Culp 表示，出售給丹納赫的交易是扭轉這家擁有126年曆史的企業集團的一個關鍵里程碑。他在丹納赫擔任首席執行官已有10多年，直到2014年。
"It demonstrates that we are executing on our strategy by taking thoughtful and deliberate action to reduce leverage and strengthen our balance sheet," he said in a statement announcing the deal.
“這表明，我們正在執行我們的戰略，採取深思熟慮和審慎的行動，以減少槓桿和加強我們的資產負債表，”他在一份聲明中宣佈這筆交易。
GE said it would get $21 billion in cash from medical equipment maker Danaher, which will assume of certain GE's pension liabilities.
通用電氣表示，將從醫療設備製造商丹納赫獲得210億美元現金，後者將承擔通用電氣的某些養老金責任。
The biopharma business, part of its life sciences unit, generated revenue of about $3 billion in 2018. It makes instruments and software that support the research and development of drugs.
生物製藥業務是其生命科學部門的一部分，2018年實現收入約30億美元。它生產支持藥物研發的儀器和軟件。
The other business housed in the life sciences unit, which makes molecular imaging consumables for radiology customers, will remain within the company's healthcare portfolio, GE said.
GE 表示，生命科學部門的另一項業務仍將保留在公司的醫療產品組合中，該部門為放射學客戶生產分子成像耗材。
Danaher develops technology for the dental, life sciences, diagnostics and environmental industries.
丹納赫公司為牙科、生命科學、診斷和環境行業開發技術。
GE, which reported lower-than-expected fourth-quarter profit in January, said it would provide its 2019 outlook on a conference call on March 14.
通用電氣( GE )表示，將在3月14日的電話會議上提供2019年的前景。該公司1月份公佈的第四季度利潤低於預期。
閱讀更多 匯眾醫療 的文章
